Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

  • End date
    Sep 30, 2023
  • participants needed
  • sponsor
    Mabwell (Shanghai) Bioscience Co., Ltd.
Updated on 26 January 2021


In the study, subjects will scheduled to undergo four 21-days cycles of chemotherapy treatment. Three group were treated with MW05 300 g/kg or MW05 500 g/kg or PEG-rhG-CSF 100 g/kg on the 3th day of each cycle randomized 1:1:1 .

The dose of the experimental drug MW05 in phase III were determined by independent data monitoring committee (IDMC) according to the efficacy and safety of phase II. Subjects were randomly divided into two groups 1:1 to received either MW05 or PEG-rhG-CSF(100 g/kg) on the 3th day of each chemotherapy cycle.


Study Stage: Phase II/III Study Population Female patients with breast cancer will be enrolled to receive at least 4 cycles of TC chemotherapy, that is: Docetaxel 75 mg/m2 and Cyclophosphamide 600 mg/m2.

Study Design: A multi-center, randomized, open-label, active-controlled phase II/III clinical trial

Condition Breast Cancer Female
Treatment PEG-rhG-CSF, MW05
Clinical Study IdentifierNCT04554056
SponsorMabwell (Shanghai) Bioscience Co., Ltd.
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Are you female?
Do you have any of these conditions: Do you have Breast Cancer Female??
1870 years old female(including threshold)
Diagnosed with breast cancer
Patients planned to receive TC chemotherapy
Estimated survival time 3 months, and could received at least 4 cycles chemotherapy treatment
Have suitable organs and hematopoietic function
ECG examination is normal or abnormal has no clinical significance
B-ultrasound examination of abdomen showed no obvious abnormality of spleen
Willing to sign the informed consent form and able to comply with protocol requirements
Non-menopausal or non-surgically sterilized female subjects, the blood pregnancy test results must be negative at the time of screening, and within at least 3 months from the signing of the informed consent form to the end of the last administration, consent to abstinence or the use of effective contraceptive methods

Exclusion Criteria

History of other malignant tumors (skin basal cell carcinoma, skin squamous cell carcinoma and / or carcinoma in situ after radical resection can be included in the group after being cured for more than 5 years)
Primary hematological diseases, including but not limited to myelodysplastic syndrome, aplastic anemia, sickle cell anemia and other hematological diseases that affect bone marrow hematopoiesis
With known central nervous system metastasis or suspected central nervous system metastasis based on clinical manifestations
With previous history of bone marrow transplantation and / or stem cell transplantation
Currently uncontrolled infections or have received systematic anti-infective therapy within 72 hours before randomization
Serious chronic diseases of important organs such as kidney and liver
Severe heart disease, including but not limited to:history of congestive heart failure (New York College of Cardiology [NYHA] II or higher heart disease)Angina pectoris that needs to be treated with anti-angina pectoris drugsUncontrollable hypertension (systolic blood pressure 180 mmHg and / or diastolic blood pressure 100 mmHg)Arrhythmias requiring drug treatment
Severe diabetes (such as fundus disease or diabetic foot), or blood sugar is still not well controlled after active treatment
Surgery within 2 weeks before chemotherapy or radiotherapy within 4 weeks (except for patients whose physical condition has recovered and can accept the relevant procedures of this study, as determined by the researchers)
Adverse reactions from previous treatments failed to recover to CTCAE v5.0 score 1 (except for alopecia and other toxic reactions that researchers believe do not affect the safety of this chemotherapy)
According to the researchers, there are serious risks to the safety of patients or concomitant diseases that affect the completion of the study
Participated in clinical trials of any other drugs within 4 weeks
Received the same efficacy drugs(such as PEG-rhG-CSF or rhG-CSF, etc.) are still in 5 half-lives or within 28 days (whichever is shorter)
With allergic disease or allergic constitution, and who have previously been allergic to any drug or its components in this trial
Active hepatitis B (HBsAg positive and HBV-DNA copy number greater than the normal limit) and / or active hepatitis C (hepatitis C virus antibody positive and HCV-RNA copy number greater than the normal limit) and / or human immunodeficiency virus antibody positive and / or Treponema pallidum antibody
Drug abuse. history or drug abusers
Pregnant or lactating women
Who have been judged by the researchers to be unsuitable for selection or who are not suitable for other reasons
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note